

Contents

1. History of Development of SGLT-2 Inhibitors	1
<i>Jubbin Jacob, Charles Antonypillai</i>	
2. Pharmacological Profile of Gliflozins: Sodium Glucose Co-transporter-2 (SGLT-2) Inhibitors	10
<i>Savita Verma, Himanshu Gupta</i>	
3. SGLTi and Glycemic Control: A 2018 Update	19
<i>Deep Dutta, Shahjada Selim, Indira Maisnam</i>	
4. SGLT-2 Inhibitors and Blood Pressure Control	25
<i>Dina Shrestha, Deepak Khandelwal</i>	
5. SGLT-2 Inhibitors and Weight Loss	33
<i>Rajiv Singla, Sameer Aggarwal</i>	
6. SGLT-2 Inhibitors and Pleotropic Benefits	37
<i>Rakesh Goyal, Vishal Bhatia</i>	
7. SGLT-2 Inhibitors in Combination with Insulin	42
<i>Vineet Surana, Ye Myint</i>	
8. SGLT-2-i and GLP1-RA Combination Therapy	49
<i>Belinda George, Ankia Coetzee</i>	
9. Combination of SGLT-2 Inhibitors and DPP4 Inhibitors	60
<i>Saptarshi Bhattacharya, Rakesh Malhotra</i>	
10. Combination of SGLT-2 Inhibitors with Other Oral Hypoglycemic Drugs	66
<i>Sachin Chhittawar, Nitesh, Abhinav Nair</i>	
11. Combined SGLT-2 and SGLT-1 Inhibitor	71
<i>Ameya Joshi, Sandeep Chaudhary</i>	
12. SGLT-2 Inhibitors in Advanced Clinical Development	78
<i>Emmy Grewal, Gagan Priya</i>	
13. SGLT-2 Inhibitors and Heart Failure: Diabetes and Beyond	89
<i>Nikhil Gupta, Om J Lakhani</i>	

14. SGLT-2 Inhibitors in Nondiabetic Kidney Disease	99
<i>Sunil Kumar Kota, Joel Rodriguez Saldana</i>	
15. Sodium-Glucose Transporter 2 (SGLT-2) Inhibitors: Current Status in Clinical Practice	106
<i>Manoj Kumar, Ashok Kumar, Andrew E Uloko</i>	
16. SGLT-2 Inhibitors and Diabetic Kidney Disease	116
<i>Atul Dhingra, Philip A Kalra</i>	
17. SGLT-2 Inhibitors: Cardiology Perspective	123
<i>Dheeraj Kapoor, Ranjana Bhatt, Syed Abbas Raza</i>	
18. SGLT-2i: Risk-Benefit Analysis	130
<i>Ashish Sehgal, Mohammed Wali Naseri</i>	
<i>Index</i>	<i>137</i>